dokumendiregister.ee
OtsingAsutusedMCP
Otsing›Sotsiaalministeerium
Sissetulev kiriAvalik

Pöördumine

Sotsiaalministeerium · 11. mai 2020
Viit
1.4-2/1607-1
Registreeritud
11. mai 2020
Dokumendi liik
Sissetulev kiri
Adressaat
Westline Medicare OÜ
Saabumis/saatmisviis
e-post
Funktsioon
1.4 EL otsustusprotsess ja rahvusvaheline koostöö
Sari
1.4-2 Rahvusvahelise koostöö korraldamisega seotud kirjavahetus (Arhiiviväärtuslik)
Toimik
1.4-2/2020
Vastutaja
Madis Tõns (Sotsiaalministeerium, Kantsleri vastutusvaldkond, Terviseala asekantsleri vastutusvaldkond, Ravimiosakond)

Failid

  • 📎E-kiri.pdf104 KB
  • 📎Rapid Antibody COVID-19 Test.pdf219 KB
  • 📎Vivalytic Brochure.pdf4240 KB

Sisu (failidest)

Saatja: Tatiana Bronzova <[email protected]> Saadetud: 11.05.2020 12:16 Adressaat: Heli Laarmann <[email protected]> Koopia: SM Info <[email protected]>; <[email protected]>; <[email protected]>; <[email protected]>; <[email protected]> Teema: Mass Testing for Coronavirus - Digital Platform Solution Dear Mrs.Laarmann, Regarding positively changed status of Corona virus epidemic in Estonia and in Finland and Estonian Governments decision (on 9th of April) to start mass testing of people for Coronavirus based on suitable antibody tests, we contacted on the 28th of April AS Tallink Grupps Mr. Joonas Joost (Advisor for Management) and their Team for New Safety Measures with our suggestion (see email below) and notice of desire to co-operate with them. Because we observed from the news that Estonian Government has made a decision (on 8th of May) that restrictions for border crossings between Estonia and Finland will be eased and voluntary Corona testing - arranged by the Ministry of Social Affairs- will be carried out on board of ships travelling between Finland and Estonia from May 14 to 19, we dare to approach now also you with our previous suggestion. We really believe that our Digital COVID-19 Rapid Tests and Diagnostic Platform could be a part of modern solution for mass testing of Corona virus. Naturally it is matched to use our present Lateral Flow Test kits but its software algorithms are easily adaptable to utilize images from any Lateral Flow Test kits. We would like to underline that the Analytics Secure Cloud (Amazon AWS) is easy to connect to Third-Party System like a local EHR (Electronic Health Record). Our technology is used already on 4 continents - it is approved by US FDA, Chinese FDA, and it is CE marked. Thus, we would like to suggest, would it be possible for you to consider our Digital COVID-19 Rapid Tests and Diagnostic Platform as an alternative for mass testing of COVID-19. We would be pleased to deliver for you more information about our product. We can deliver our test kit samples for you for analysis and we can organize a Skype meeting with you and our Team of specialists. If you see our contribution valuable for Estonia, we are happy to co- operate with you. Best regards Board member Tatiana Bronzova Board member Freddy E.Descamps MD, MPH, FACPM Consultant Tapio Mäenpää D.Sc. T +372 5299742 | M +37254005045 | Westline Medicare OÜ | Pärnu mnt 139d, Tallinn, Harju maakond, 11317 Estonia , Reg.N: 12345460 VAT: EE101593173, IBAN:EE97 2200 2210 5595 6344 , SWIFT/BIC: HABAEE2X Swedbank AS Liivalaia 8,15040 Tallinn Estonia , email: Îò: Tatiana Bronzova <[email protected]>Äàòà: âòîðíèê, 28 àïðåëÿ 2020 ã., 14:48Êîìó: <[email protected]>Êîïèÿ: <[email protected]>Òåìà: Cooperation A Way to Return to Normal Business after Corona peak Dear Sir/Madam, Does your company have a strategy how to proceed and return to normal business when the Corona restrictions are gradually phased out, as is currently being planned e.g. in Finland. Have you considered with your stakeholders what ways to move into normal business. Have you considered proactive measures that would support e.g. Finlands so-called hybrid strategy for Corona or Estonian's mass tests option to determine latency of COVID-19. We would like to suggest, weather a strategy similar to the Emirates Airlines has applied to its business, could be possible for you and your stakeholders: "Emirates Airlines has begun conducting rapid coronavirus tests on passengers before they board a flight." A modern, proven technology to support this kind of strategy exists. We would be pleased to present to you and your stakeholders Rapid Coronavirus Test technology that fulfills these requirements. We can offer two new technologies: Digital COVID-19 Rapid Tests and Diagnostic Platform We would like to introduce to you our partners developed mobile diagnostics Point of Care platform which can detect IgM and IgG antibodies and provide a digital analysis. It integrates diagnostics, mobile technology and cloud computing into one platform. Actually it turns a smartphone into a virtual lab where the results are displayed, offering faster, easier, and precise diagnostics, enabling quick action and treatment.In addition, the cost of the test is significantly low as compared to PCR test.The biggest advantage is that it creates a digitised diagnostic data with geographical mapping that can help monitor and control outbreaks. Digital test kit works in the same way blood sugar is tested by using a pinprick on patients thumbs. The results can be obtained within minutes. The rapid test kits, with lgM&lgG sensitivity of 97.6% and specificity 100%, can help save time and reduce direct contact as one counter set up at a Point of Care location can test hundreds of patients. Test is done in three steps 1. Take a test - Nurse or doctor performs the diagnostic test with a test kit 2. Read the test - Scanned in a mobile phone using Immediate Diagnostics and Analytics application 3. Store result - Immediate Diagnostics and Analytics Secure Cloud checks the result immediately for diagnosis After the test is conducted, the complete data with patient information and GPS location is automatically sent to the Immediate Diagnostics and Analytics Secure Cloud and is available for the health care professionals and stakeholders.The experts can then accordingly guide the person on the ground. If it is negative, no action is required. If it is positive, guide them to the treatment services. If there is some error, test again. Benefits of the Digital COVID-19 Rapid Test * It enables faster, convenient, precise and cost-effective diagnostics combining mobile technology and cloud computing. * Lateral flow test quality control and quality assurance. * As compared to PCR tests, the digital test reduces both human error and technology gaps. * It saves time and cost as the results are recorded digitally and uploaded to the cloud platform instead of manual reports and a visit to labs. * Seamless data management integration into client / stakeholder information systems. * Reduce direct contact and virus exposure, as patients do not need to go to hospitals or clinics. * Test results obtained in minutes whereas the PCR tests results may take 24 to 48 hours. * It can help generate and divide data by age, gender and locations, publishing visual reports and producing heat maps of infections. * Disease surveillance and real time epidemic alerts via interactive mapping. Westline Medicare OÜ represents new rapid COVID-19 test method which can identify the COVID-19 strain. This new method is developed by Randox Biosciences and Bosch Healthcare Solutions. Westline Medicare OÜ is a distributor Randox Biosciences on the territory in Estonia. The new test will utilise Randox Biochip Technology, with results available from the Vivalytic - the universal diagnostic platform for point of care within 2 1/2 hours. The Randox test is able to differentiate between the 10 following viral respiratory pathogens, this screening is unique to Randox and will save the laboratory both time and money running many separate PCR tests. The WHO recommends testing for multiple respiratory pathogens as co- infections can occur. Our testing methods offered on both the vivalytic and evidence investigator use multiplex PCR followed by detection using our unique biochip technology. The biochip array technology allows simultaneous detection of multiple analytes from a single sample. Each biochip has duplicate discrete testing regions for the 10 viral respiratory pathogens as internal QC to prevent reporting of false positive results. The biochip detection is based on chemiluminescence, which is very sensitive. Currently in the hospital, they are conducting RT-PCR for the SARS-Cov-19 E gene to screen followed by confirmation RT-PCR of the RDRP gene. This is a very time consuming process. The Randox panel allows one test to cover both the screening and confirmation PCR for SARS-Cov-19, as well as 9 other viral pathogens including other Corona virus subtypes which all present the same symptoms. The updated WHO testing recommends testing for multiple pathogens as co-infections are very common. Analysers for IVD: Vivalytic: * One patient sample in per cartridge. Each cartridge can test for 10 viral pathogens including the COVID-19, giving results in 2 1/2 hours. * This machine is designed as a POC machine and can be used outside the laboratory by non-laboratory trained staff. Eg. Can be used on cruise ship, nurse in GP office, airport etc. Please find attached a brochure of this new testing method. If you have anything to ask - we are pleased to answer you. Best regards Board member Tatiana Bronzova Board member Freddy E.Descamps MD, MPH, FACPM Consultant Tapio Mäenpää D.Sc. T | M | Westline Medicare OÜ | Pärnu mnt 139d, Tallinn, Harju maakond, 11317 Estonia Reg.N: VAT: EE101593173 IBAN:EE97 2200 2210 5595 6344 , SWIFT/BIC: HABAEE2X Swedbank email: Why Do We Need Antibody Tests for COVID-19 Diagnosing viral infections currently relies on two major methodologies: Reverse Transcription Quantitative Polymerase Chain Reaction (RT-qPCR) and serological immunoassays that detect viral-specific antibodies (IgM and IgG) or antigens. Although, RT-qPCR is a highly sensitive test for SARS-CoV-2 (the virus that causes COVID-19) it has its limitations. RT-qPCR requires high-quality nasopharyngeal swabs containing sufficient amounts of viral RNA. This can be a challenge because the amount of viral RNA not only varies tremendously between patients, it can also varies within the same patient depending on the timing of the test and the start of the infection and/or the onset of symptoms. In addition, nasopharyngeal swabs are not only very unpleasant to the patient, the sampling techniques vary significantly from nurse to nurse. Without sufficient viral RNA RT-qPCR can return a false negative test result. RT-qPCR also requires highly trained personnel to perform complex RNA extraction steps and PCR. Normally, this would not be a problem when testing a few samples. RT-qPCR becomes an issue when dealing with a global pandemic with potentially thousands of people to test. This may lead to delays in testing as medical facilities become overloaded. According to recent studies, false negative results obtained with RT-qPCR are more common than initially thought. False negative results can have critical impacts on the current efforts to contain the SARS-CoV-2 outbreak as infected patients are mistakenly given a permission to return home, return to work and possibly infecting others. Relying solely on nucleic acid tests to diagnose SARS-CoV-2 may be a risky strategy. As such, needs to add independent testing methodologies to complement RT-qPCR are becoming increasing important. IgG/IgM serological tests offer some advantages over RT-qPCR. Firstly, serological tests detect human antibodies which are known to be much more stable than viral RNA. As a result, IgM/ IgG serological specimens are less sensitive to mistakes during collection, transport, storage and testing than RT-qPCR specimens. Secondly, because antibodies are typically uniformly distributed in the blood, serological specimens have much less variations than nasopharyngeal viral RNA specimens and can be easily collected with minor phlebotomy discomfort to the patient. Thirdly, unlike RT-qPCR, serological tests can detect past infection because virus- specific antibodies can persist in the blood for several weeks/months after onset of symptoms. IgM/IgG serological tests also have some limitations, mainly related to the slow pace of the human antibody response to SARS-CoV-2. According present knowledge SARS-CoV-2 antibodies may not be detectable before 3 days after onset of symptoms (or at least 7 to 10 days after infection). While IgM/IgG serological tests alone may not be enough to diagnose COVID-19, they can be a valuable diagnostic tool when combined with RT-qPCR. In addition, because of their scalability, serological assays can be used in large-scale, whole-population, testing to assess the overall immune response to the virus and identify asymptomatic carriers of the virus. 20-80% of COVID-19 cases are estimated to be asymptomatic. How the IgM/IgG Serological Test Results Should be Interpreted The IgM/IgG serological assay is designed to complement RT-qPCR in the diagnosis of SARS- CoV-2 infections. Table 1 shows the clinical interpretation of all possible cases that can observed when testing a patient with both RT-qPCR and an IgM/IgG serological test. Table 1: Clinical Significance of an IgM/IgG Serological Test Result This table is based on the current knowledge about the rise and fall of SARS-CoV-2 RNA and antigens, IgM antibody and IgG antibody and the correlation of these level variations with the initial time of infection, onset of symptoms and recovery phase. As shown in Figure 1, serological tests are recommended to be used on patients at least 3 days after onset of symptoms or 7-10 days after infection with the virus. The key conclusion is that the RT-qPCR testing may be appropriate for the detection of the SARS-CoV-2 virus during the acute phase, but IgM/IgG is an appropriate test during the chronic phase. Since the exact time of infection is often unknown, combining RT-qPCR and IgM/IgG testing can improve the accuracy of the COVID-19 diagnosis. Figure 1: Variation of the Levels of SARS-CoV-2 RNA and Antigen, IgM and IgG after infection. Why Antibody Tests Should Be Used An antibody test method, or serology test, that detects the presence of SARS-CoV-2 specific antibodies in the blood has recently received FDA approval in USA. Like the point of care genome tests, antibody tests are a rapid diagnostic that will give users a verdict within 10 - 15 minutes. One potential use of antibody tests is to measure the extent of the pandemic at the population or e.g. at company level. Our understanding of the disease and its projected impact in the population is weakened by our inability to monitor its spread amongst people with either mild symptoms or none at all. Another use is to measure the progress of individual infection. Antibody tests quantify the number of immunoglobulin M (IgM) and immunoglobulin G (IgG) antibodies in the blood. The presence of more IgM antibodies, which are the first to appear and mobilize against an invading organism, indicates more recent exposure to the virus. It is through this result that an asymptomatic carrier of the virus could be identified- a feature of no small importance, since “silent carriers” have played a major role in transmission. More IgG antibodies, which are virus specific and produced in later stages of infection, would lead a person to test positive for immunity, implying recovery. This unfortunately doesn’t guarantee full protection. The test won’t reveal how neutralizing, or how potent, these IgG antibodies are; nor can it determine how long they will last. Even with this taken into account, the advantages of antibody tests as a tool against infectious disease are still numerous—their low cost not least among them. Antibody tests can be administered for less than $15. The price is but a fraction of the PCR tests. No special assembly or training is required; Point-of-Care tests could be given flexible in clinics and pharmacies, or at schools, popup stations, aero ports, railway stations, etc. Successful deployment of antibody tests, will depend on their “sensitivity and specificity.” Sensitivity prevents false negatives, since a more sensitive test is more likely to actually detect it. Specificity, on the other hand, prevents false positives, since a less specific test may pick up on antibodies against a virus other than SARs-CoV-2. Today Antibody Test kits have sensitivity and specificity values for IgM and IgG over 97%. VIVALYTIC THE ALL IN ONE MOLECULAR SOLUTION CONTENTS 1 Vivalytic & Cartridges Vivalytic 03 Vivalytic Cartridges 05 Vivalytic Workflow 07 2 Vivalytic Tests Respiratory Infections Testing 11 Genitourinary Infections Testing 13 Hospital Acquired Infections Testing 14 3 Vivalytic Specification Specifications 19 Vivalytic Up 20 Vivasuite 20 4 Vivalytic Test Menu Test Menu 23 01 Vivalytic & Cartridges 03 Vivalytic & Cartridges Vivalytic Vivalytic brings innovation to the Molecular Diagnostic testing market. It is the result of a collaboration involving Bosch, the German technology giant, and Randox Laboratories, a global IVD company. With over 35 years experience in assay development, Randox is dedicated to improving global healthcare. Vivalytic enables sample to answer, cartridge-based Molecular Diagnostic testing. The Vivalytic platform is capable of both Hi-Plex and Lo-Plex testing. Nucleic acid extraction, PCR amplification followed by a suite of detection methods are combined in a truly revolutionary, fully automated platform. Manual preparation, cold chain reagents and the use of multiple devices are no longer required. No further peripherals such as a laptop, keyboard, barcode scanner or filling station are required, making Vivalytic a unique space-saving, hygienic solution for Molecular Diagnostic testing. Ease of Use Unique Test Menu Fully Automated Fast Hi-Plex & Lo-Plex Wireless Test Results Capabilities Connectivity 05 Vivalytic & Cartridges Vivalytic & Cartridges 06 Vivalytic Cartridges Hi-Plex Vivalytic Cartridges Powered by Randox Biochip Array Technology Vivalytic cartridges are compact, technologically advanced Molecular Diagnostic tests utilising micro-fluidics to enable simple and accurate diagnostic testing. Vivalytic cartridges are powered by a variety of technologies, dependent upon the test application. Biochip Array Technology enables sample to answer multiplex Molecular Diagnostic testing. Every biochip-powered cartridge Hi-Plex and Lo-Plex tests can be analysed on the Vivalytic. Hi-Plex tests utilise Randox patented Biochip Array Technology, produces multiple test results from each patient sample. The intelligent, chemically activated 9x9mm ceramic biochip acts as enabling end-point qualitative PCR and providing multiple test results from each sample. Lo-Plex tests are based on a variety a solid phase reaction surface. of detection methods including real-time qualitative PCR and melting curve analysis. The biochips are pre-fabricated with spatially discrete tests regions (DTRs). Each DTR represents an individual test and each biochip can contain up to 44 DTRs. Each DTR can be occupied with oligonucleotides specific to a pathogen of interest. The Hi-Plex capabilities of Biochip Array Technology eliminate the need to run multiple time consuming and sample intensive PCR assays. The biochip detection system is based on a chemiluminescent signal. This is the emission of light, without heat, due to an enzymatic chemical reaction. The light emitted from the chemiluminescent reaction that takes place in each DTR is simultaneously detected and quantified using a Charge - Coupled Device (CCD) Camera. This CCD Camera simultaneously records the light emission from all the discrete test sites on each biochip. The Vivlaytic automatically generates a result report for all targets. All Reagents On-Board Room Temperature Storage 44 Discrete Testing Regions Multiplex Technology 9x9mm Biochip Multiple Sample Types 5 Quality Control Regions Minimal Contamination Risk 185mm (L) 75mm (W) 17mm (D) *Actual Size 07 Vivalytic & Cartridges Vivalytic Workflow 4 Easy Steps for Optimised Workflow Intuitive engineering of Vivalytic ensures the analyser is user friendly. The process of patient sample to result comprises a very simple 4 step workflow. To begin the test, the user scans or enters sample information. The cartridge code is then scanned into the embedded Vivalytic software. The user then adds sample into the dedicated cartridge slot, closes the lid and inserts the cartridge into the Vivalytic. The touchscreen display will countdown the time remaining to test completion. Results will be displayed on the screen. Multiple Vivalytics can be wirelessly connected allowing the user to control multiple tests at one time all reporting to a master Vivalytic platform. AWARD-WINNING DESIGN DELIVERS AN UNCOMPLICATED USER EXPERIENCE 1 2 Scan/Input Sample Code Scan/Input Cartridge Code 3 4 Insert Sample into Test Insert Cartridge: Cartridge and Close Cover Extraction - PCR - Detection 02 Vivalytic Tests 11 Vivalytic Tests Vivalytic Tests 12 Respiratory Respiratory Tract Infections (RTI) Chronic Lung Disease (CLD) The Respiratory Tract Infections is the most comprehensive screening test for infections of both the upper and The Chronic Lung Disease cartridge is a world leading multiplex test, detecting 132 species associated with long term lower respiratory tracts. It simultaneously detects 14 viral and 8 bacterial infections. The test can be carried out with lung disease e.g. Cystic Fibrosis and Chronic Obstructive Pulmonary Disease (COPD). The 132 species are simultaneously nasopharyngeal swabs, sputum or broncheoalveolar lavage (BAL). detected across this 32-plex array and includes bacterial, viral, fungal targets and an antibiotic resistance marker from a single sputum sample. Furthermore, the MecA antibiotic resistance marker is included to assist antibiotic stewardship. Sample Type: Nasopharyngeal Swab, Sputum, BAL Sample Volume: 200 μL Sample Type: Sputum Detection Method: Biochip Array Technology Sample Volume: 200 μL Detection Method: Biochip Array Technology VIRUSES VIRUSES Influenza A Coronavirus OC43/HKU1 Parainfluenza virus 3 Adenovirus Respiratory syncytial virus B Influenza virus B Influenza B Enterovirus A/B/C Parainfluenza virus 4 Adenovirus A/B/C/D/E Metapneumovirus Respiratory syncytial virus A/B Metapneumovirus Rhinovirus A/B/C Bocavirus 1/2/3 Parainfluenza virus 1 Rhinovirus A/B/C Respiratory syncytial virus A Influenza virus A Coronavirus 229E/NL63 Parainfluenza virus 2 BACTERIA BACTERIA Achromobacter xylosoxidans Moraxella catarrhalis Pseudomonas aeruginosa Bordetella pertussis Mycoplasma pneumoniae Staphylococcus aureus Bordetella parapertussis Haemophilus influenzae Mycoplasma pneumoniae Burkholderia cepacia complex (21spp) Non-tuberculous mycobacterium (15 spp) Stenotrophomonas maltophilia Bordetella pertussis Legionella pneumophila Streptococcus pneumoniae Burkholderia cenocepacia Mycobacterium abscessus subgroup (4 spp) Streptococcus pneumoniae (21 spp) Chlamydophila pneumoniae Moraxella catarrhalis Burkholderia multivorans Mycobacterium avium complex (4 spp) Streptococcus species (19 spp) Chlamydia pneumoniae Pandoraea species (5 spp) Veillonella species (3 spp) Haemophilus influenza Prevotella species (16 spp) FUNGI Flu A/B & RSV Aspergillus fumigatus Candida albicans Exophialia dermatitidis Scedosporium species (7 spp) The Flu A/B & RSV assay utilises a one-step real-time PCR format where the automated reverse transcription of influenza ANTIBIOTIC RESISTANCE MARKERS RNA and/or RSV RNA is followed by the detection of pathogen specific genes in the same cartridge. The test can be carried out with nasopharyngeal swabs, sputum or broncheoalveolar lavage (BAL). mecA (incl MRSA) Sample Type: Nasopharyngeal Swab, Sputum, BAL Sample Volume: 200 μL Detection Method: Real-Time PCR VIRUSES Influenza A Influenza B Respiratory Syncytial Virus (RSV) 13 Vivalytic Tests Vivalytic Tests 14 Genitourinary Hospital Acquired Infections Sexually Transmitted Infections (STI) Methicillin-Resistant Staphylococcus Aureus (MRSA) The Sexually Transmitted Infections is the broadest cartridge-based STI test on the market simultaneously detecting 10 bacterial, MRSA is a qualitative test detecting and differentiating between methicillin-resistant Staphylococcus aureus (MRSA), viral and protozoan infections for a comprehensive sexual health profile. methicillin-sensitive Staphylococcus aureus (MSSA) and methicillin-resistant coagulase-negative Staphylococci (MRCoNS). A variety of swabs can be used including human nasal or nasal/throat swabs, cultures, wounds, axilla, groin and perineum swabs. Sample Type: Swab or Urine Sample Volume: 200 μL Sample Type: Swab Detection Method: Biochip Array Technology Sample Volume: 200 μL Detection Method: Real-Time PCR INFECTIONS Chlamydia trachomatis (CT) Herpes simplex virus 1 (HSV-1) BACTERIA Neisseria gonorrhoea (NG) Herpes simplex virus 2 (HSV-2) Methicillin-resistant Methicillin-sensitive Methicillin-resistant Staphylococcus aureus (MRSA) Staphylococcus aureus (MSSA) coagulase-negative Staphylococci (MRCoNS) Trichomonas vaginalis (TV) Haemophilus ducreyi (HD) Mycoplasma genitalium (MG) Mycoplasma hominis (MH) Treponema pallidum (Syphilis) (TP) Ureaplasma urealyticum (UU) Urinary Tract Infections (UTI) The Urinary Tract Infections is a market leading test detecting bacterial, fungal with associated resistance markers from a single urine sample. Identification of a multi-plex UTI can prevent further damage to the renal system including the kidneys and bladder. The various antibiotic resistance markers are included to assist antibiotic stewardship. Sample Type: Urine Sample Volume: 200 μL Detection Method: Biochip Array Technology BACTERIA Acinetobacter baumannii Escherichia coli Providencia stuartii Citrobacter freundii Klebsiella oxytoca Serratia marcescens Citrobacter koseri Klebsiella pneumoniae Staphylococcus aureus Klebsiella aerogenes Morganella morganii Staphylococcus epidermidis Enterobacter cloacae Proteus spp. Staphylococcus saprophyticus Enterococcus faecalis Pseudomonas aeruginosa Streptococcus agalactiae (GBS) Enterococcus faecium Providencia rettgeri FUNGUS Candida albicans ANTIBIOTIC RESISTANCE MARKERS mecA (incl MRSA) Trimethoprim Resistance 4 Trimethoprim Resistance 1 Trimethoprim Resistance 5 Trimethoprim Resistance 2 Van A (Vancomycin Resistance A) Trimethoprim Resistance 3 Van B (Vancomycin Resistance B) 15 Vivalytic Tests VIVALYTIC FASCINATES WITH A MARKEDLY MINIMALIST DESIGN WHOSE STRENGTH LIES IN ITS HIGH USER-FRIENDLINESS AND FUNCTIONALITY 03 Vivalytic Specifications 19 Vivalytic Specifications Vivalytic Specifications 20 Vivalytic Specifications Vivalytic Up Vivalytic is a versatile analyser suitable as a stand-alone platform. Alternatively, it can be transformed into a modular and expandable system. Stacking of the analysers provides the user with a scalable, flexible and space saving Molecular Diagnostic testing solution. Vivalytic Up offers a multi-slot, random access testing platform allowing the user the ability to use one analyser as the master user-interface that communicates with the other analysers. Integrated cable management is available allowing just one main power cable to power up to 8 analysers at one time. 400mm 388mm 204mm PERFORMANCE CHARACTERISTICS Vivasuite Analyser Type Fully Automated Sample Volume 200μl All Vivalytic analysers can be connected to Vivasuite, a valuable device management system. Vivasuite is the digital Vivalytic Relative Humidity Range Operating humidity 30-80% (not condensing) ecosystem allowing you to reduce service cost and ensures clarity of your systems. Vivasuite runs on the Bosch IoT Cloud Peripherals None Required and applies the highest standards regarding IT security and data privacy. Functionality of the Vivasuite includes registration, Weight 15KG device management and automatic software updates, giving the device administrators an informed perspective on the usage Storage Humidity 20-95% (not condensing) of the devices. Sample Types Sputum, swab, urine, blood and BAL Storage Capacity 16G Benefits Noise Output 65 dB »» Extended warranty options for connected products POWER & CONNECTIVITY »» Automatic software updates, including product releases 7" high resolution LCD (RGB)(1024x600) Display Touch-sensitive screen (responsive to lab gloves) »» Real-time monitoring of internal machine performance Electrical Data 100-240 V~, 50/60Hz, 160VA »» Monitoring of usage in remote settings SYSTEM CONNECTIONS Supports: HL7, GDT & POCT-1A Ethernet 10/100MN WiFi 2.4GHz (802.11b/g/n) Data Transfer / Connectivity Internal: Bluetooth v4.1 2.4 GHz (low energy), USB 2.0, 3 USB Ports GSM Memory Capacity 16GB 04Vivalytic Test Menu 23 Vivalytic Test Menu 24 Test Menu TEST TARGETS RESPIRATORY 14 viral targets Respiratory Tract Infection Array 8 bacterial targets Flu A/Flu B/RSV 3 viral targets 20 bacterial targets 7 viral targets Chronic Lung Infection Array 4 fungal targets 1 antibiotic resistance marker GENITOURINARY Sexually Transmitted Infection Array 10 targets 20 bacterial targets Urinary Tract Infection Array 1 fungal targets 8 antibiotic resistance markers HOSPITAL ACQUIRED INFECTIONS MRSA 3 bacterial targets Molecular Quality Solutions Randox has a strategic partnership with both Qnostics and QCMD, internationally renowned providers of IQC and EQA products for infectious diseases. Qnostics are a provider of complete QC solutions and their products can be used in the daily monitoring of assay performance. Linearity assessment, assay evaluation, validation/verification of new assays and staff training can also be facilitated using these products. QCMD also play an essential role in assuring laboratory quality by providing EQA samples across a wide range of infectious disease areas. For more information email [email protected] 55 Diamond Road, Crumlin, Co. Antrim, United Kingdom, BT29 4QY Email. [email protected] Tel. +44 (0) 28 9442 2413 randoxbiosciences.com LT735MAR19 Information correct at time of print. Randox Laboratories Limited is a subsidiary of Randox Holdings Limited a company registered within Northern Ireland with company number N.I. 614690. VAT Registered Number: GB 151 6827 08. Product availability may vary from country to country. Please contact your local Randox representative for information. Products may be for Research Use Only and not for use in diagnostic procedures in the USA.
Allikas: Sotsiaalministeerium dokumendiregister →
dokumendiregister.eeAsutusedEesti avalike dokumendiregistrite otsing · nimistu.ee andmetel